Primary cutaneous amyloidosis is a chronic itching disease.At present,there is a lack of stand-ard treatment plans for this disease,and traditional therapies such as antihistamines,thalidomide,and local glucocorticoids have poor therapeutic effects.Studies have suggested that correcting the itch-scratch-itch cycle is the key to treating primary cutaneous amyloidosis.Tofacitinib is an oral JAK inhibitor,it can significantly reduce the scratching behavior and the expression of IL-4 and IL-31 in a mouse model of atopic dermatitis.A case of primary skin amyloidosis treated with tofacitinib is reported and the related articles are reviewed.
维普
万方数据